Athersys, Inc. announced today that through its Belgian subsidiary, ReGenesys BVBA , it has entered into an agreement with a global leader in the animal health business segment to evaluate the cell therapy technology for application in a non-disclosed animal health area. Under the terms of the agreement, ReGenesys will receive an initial payment in exchange for an exclusive period to evaluate the cell therapy technology with an option to negotiate for a license for the development and commercialization of the technology for this area.
Category: Athersys
Brokerages Set $6.00 Target Price for Athersys, Inc.
Shares of Athersys, Inc. have earned a consensus broker rating score of 1.00 from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.